TAYSHA GENE THERAPIES INC. - COMMON STOCK

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

19 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19

14 Mar 2024 16:26:51 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2024 17:08:33 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

29 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

15 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

22 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

10 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

29 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

14 Nov 2023 16:08:01 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

07 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

24 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

10 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

26 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

19 Sep 2023 16:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome  

24 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results

14 Aug 2023 07:02:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces $150 Million Private Placement Financing

14 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

31 Jul 2023 08:00:00 By Nasdaq GlobeNewswire